VectorY to Present at the Bio€quity Europe Conference in May

Written By Sariette Witte

Amsterdam, The Netherlands, 14 April 2023 – VectorY Therapeutics, a biotech company developing disease-modifying vectorized antibody therapies for the treatment of neurodegenerative diseases, today announces VectorY management will be participating in 1:1 meetings and give a company presentation during the 2023 Bio€quity Europe conference to be held May 14-16 in Dublin, Ireland.

Company presentation

Presenter: Elena Ritsou, Chief Corporate Officer

Date and time: Monday May 15 at 3:57 PM IST during the “Neurology, neurodegeneration and autoimmunity” track

About VectorY

VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease. For more information, see www.vectorytx.com.

Sariette Witte
Previous

VectorY to Present at the ASGCT Annual Meeting in May 2023
Next

VectorY to Participate in Key Sector Conferences in April 2023